Abstract:Background: The method used to model general population mortality estimates in cohort models can make a meaningful difference in appraisals; particularly in scenarios involving potentially curative treatments where a prior National Institute for Health and Care Excellence (NICE) appraisal demonstrated that this assumption alone could make a difference of ~£10,000 to the incremental cost-effectiveness ratio. Objective: Our objective was to evaluate the impact of different methods for calculating general population mortality estimates on the predicted total quality-adjusted life expectancy (QALE) as well as absolute and proportional quality-adjusted life year (QALY) shortfall calculations. Methods: We employed three distinct methods for deriving general population mortality estimates: firstly, utilizing the population mean age at baseline; secondly, modelling the distribution of mean age at baseline by fitting a parametric distribution to patient-level data sourced from the Health Survey for England (HSE); and thirdly, modelling the empirical age distribution. Subsequently, we simulated patient age distributions to explore the effects of mean starting age and variance levels on the predicted QALE and applicable severity modifiers. Provided sample code in R and Visual Basic for Applications (VBA) facilitates the utilization of individual patient age and sex data to generate weighted average survival and health-related quality of life (utility) outputs. Results: We observed differences of up to 10.4% (equivalent to a difference of 1.01 QALYs in quality-adjusted life-expectancy) between methods using the HSE dataset. In our simulation study, increasing variance in baseline age diminished the accuracy of predictions relying solely on mean age estimation. Differences of -0.30 to 2.24 QALYs were found at a standard deviation of 20%; commonly observed in trials. For potentially curative treatments this would represent a difference in economically justifiable price of -£4,500-+£33,600 at a cost-effectiveness threshold of £30,000 per QALY for a treatment with a 50% cure rate. For lower baseline ages, the population mean method tended to overestimate QALE, whereas for higher baseline ages, it tended to underestimate QALE compared with individual patient age-based approaches. The severity modifier assigned did not vary, however, apart from simulations with means at the extremes of the age distribution or with very high variance. Conclusions: Our analysis underscores the necessity of accounting for the distribution of mean age at baseline, as failure to do so can lead to inaccurate QALE estimates, thereby affecting calculations of incremental costs and QALYs in models, which base survival and quality of life predictions on general population expectations. We would recommend that patient age and sex distribution should be accounted for when incorporating general population mortality in economic models. Provided sufficient sample size, utilizing the observed empirical distribution for the expected population in clinical practice is likely to yield the most accurate results. However, in the absence of patient-level data, selecting a suitable parametric distribution is recommended.

Direct Healthy Life Expectancy Estimates from Life Tables with a Sullivan Extension. Bridging the Gap Between HALE and Eurostat Estimates

Verifying the HALE measures of the Global Burden of Disease Study: Quantitative Methods Proposed

Relation of the Weibull Shape Parameter with the Healthy Life Years Lost Estimates: Analytic Derivation and Estimation from an Extended Life Table

A Method for Estimating the Total Loss of Healthy Life Years: Applications and Comparisons in UK and Scotland

The Health Status of a Population: Health State and Survival Curves, and HALE Estimates

Modeling the Health Expenditure in Japan, 2011. A Healthy Life Years Lost Methodology

Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010

Incidence-based Estimates of Healthy Life Expectancy for the United Kingdom: Coherence between Transition Probabilities and Aggregate Life Tables

Inequalities in healthy life years in the 25 countries of the European Union in 2005: a cross-national meta-regression analysis

The Health State Function, the Force of Mortality and other Characteristics resulting from the First Exit Time Theory applied to Life Table Data

A Life Expectancy Study based on the Deterioration Function and an Application to Halley's Breslau Data

Estimating Disease-Free Life Expectancy Based on Clinical Data from the French Hospital Discharge Database

Fuzzy clustering of the healthy life expectancy decomposition: A multi-population analysis

[Measurement and Algorithm of Healthy Life Expectancy: a Scoping Review].

[Analysis of Healthy Life Expectancy and Related Socioeconomic Influencing Factors among the Middle-Aged and Elderly in China, the United States, and the European Union].

The Impact of the Approach to Accounting for Age and Sex in Economic Models on Predicted Quality-Adjusted Life-Years

Mortality and life expectancy forecasting for a group of populations in developed countries: A multilevel functional data method

lillies: An R package for the estimation of excess Life Years Lost among patients with a given disease or condition

Properties of a Stochastic Model for Life Table Data: Exploring Life Expectancy Limits

Estimating Complete Life Tables for Populations with Limited Size: From Graduation to Equivalent Construction

A comparative, correlate analysis and projection of global and regional life expectancy, healthy life expectancy, and their GAP: 1995-2025